SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-012264
Filing Date
2024-08-14
Accepted
2024-08-14 16:45:28
Documents
72
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rnaz-20240630x10q.htm   iXBRL 10-Q 1244463
2 EX-31.1 rnaz-20240630xex31d1.htm EX-31.1 17023
3 EX-31.2 rnaz-20240630xex31d2.htm EX-31.2 17154
4 EX-32.1 rnaz-20240630xex32d1.htm EX-32.1 7097
5 EX-32.2 rnaz-20240630xex32d2.htm EX-32.2 6166
  Complete submission text file 0001558370-24-012264.txt   5852433

Data Files

Seq Description Document Type Size
6 EX-101.SCH rnaz-20240630.xsd EX-101.SCH 52160
7 EX-101.CAL rnaz-20240630_cal.xml EX-101.CAL 35330
8 EX-101.DEF rnaz-20240630_def.xml EX-101.DEF 146507
9 EX-101.LAB rnaz-20240630_lab.xml EX-101.LAB 415645
10 EX-101.PRE rnaz-20240630_pre.xml EX-101.PRE 306948
75 EXTRACTED XBRL INSTANCE DOCUMENT rnaz-20240630x10q_htm.xml XML 779753
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

IRS No.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40363 | Film No.: 241208994
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)